Competition is intensifying in the transcatheter aortic valve replacement (TAVR) market, but Edwards Lifesciences Corp. (Irvine, Calif.) (NYSE: EW) executives assured investors Wednesday the company is not resting on its TAVR laurels and still expects double-digit growth from its transcatheter heart valve therapy (THVT) business in 2016. Read More
